ImmunityBio $500 million at-the-market offering
Davis Polk advised the sales agent on the SEC-registered at-the-market offering by ImmunityBio, Inc. of its common stock for up to an aggregate amount of $500 million.
Based in Los Angeles, California, ImmunityBio, Inc. is an immunotherapy company working to advance the next-generation of immunotherapies and to address unmet needs within oncology and infectious disease.
The Davis Polk corporate team included partner Alan F. Denenberg and associates Bryan M. Quinn and Lawrence Edward Traylor Jr. The intellectual property and technology transactions team included partner David R. Bauer and associate Brette L. Trost. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.